• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

C反应蛋白-白蛋白-淋巴细胞指数作为肾癌手术患者病情进展的新型生物标志物

C-reactive Protein-albumin-lymphocyte Index as a Novel Biomarker for Progression in Patients Undergoing Surgery for Renal Cancer.

作者信息

Hirata Hiroshi, Fujii Nakanori, Oka Shintaro, Nakamura Kimihiko, Shimizu Kosuke, Kobayashi Keita, Hiroyoshi Toshiya, Isoyama Naohito, Shiraishi Koji

机构信息

Department of Urology, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.

出版信息

Cancer Diagn Progn. 2024 Nov 3;4(6):748-753. doi: 10.21873/cdp.10391. eCollection 2024 Nov-Dec.

DOI:10.21873/cdp.10391
PMID:39502622
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11534045/
Abstract

BACKGROUND/AIM: Some patients with renal cell carcinoma (RCC) develop early or late recurrence after surgery. However, there is no clear consensus on which patients with postoperative RCC should be treated. This study aimed to establish a biomarker for selecting patients who are at a higher risk of relapse following renal cancer surgery.

PATIENTS AND METHODS

A total of 378 patients who underwent nephrectomy or partial nephrectomy for a diagnosis of RCC at our hospital were included, with a focus on pT3 cases at high risk of recurrence. Factors associated with postoperative progression, including pathological and hematological parameters, were examined.

RESULTS

Sarcomatoid features, Fuhrman grade 4, and C-reactive protein-albumin-lymphocyte (CALLY) index were statistically significant predictive factors for progression-free survival after surgery (p<0.0011, p=0.0047, and p<0.0001, respectively). In the multivariate Cox proportional regression analysis, the CALLY index was the most statistically significant predictor of the risk of postoperative recurrence (p=0.0002).

CONCLUSION

In addition to the existing risk factors for RCC recurrence, such as sarcomatoid features and Fuhrman grade, we propose that the CALLY index is a predictor of postoperative recurrence and that patients with a low CALLY index are good candidates for postoperative treatment. Our study may help select patients with pT3 disease with a high risk of recurrence who require postoperative treatment.

摘要

背景/目的:一些肾细胞癌(RCC)患者在手术后会出现早期或晚期复发。然而,对于哪些术后RCC患者应接受治疗,目前尚无明确共识。本研究旨在建立一种生物标志物,用于筛选肾癌手术后复发风险较高的患者。

患者与方法

纳入我院378例因诊断为RCC而接受肾切除术或部分肾切除术的患者,重点关注复发风险较高的pT3病例。研究了与术后进展相关的因素,包括病理和血液学参数。

结果

肉瘤样特征、Fuhrman 4级以及C反应蛋白-白蛋白-淋巴细胞(CALLY)指数是术后无进展生存期的统计学显著预测因素(分别为p<0.0011、p=0.0047和p<0.0001)。在多变量Cox比例回归分析中,CALLY指数是术后复发风险最具统计学意义的预测因素(p=0.0002)。

结论

除了RCC复发的现有风险因素,如肉瘤样特征和Fuhrman分级外,我们提出CALLY指数是术后复发的预测指标,CALLY指数低的患者是术后治疗的良好候选者。我们的研究可能有助于筛选出复发风险高且需要术后治疗的pT3疾病患者。

相似文献

1
C-reactive Protein-albumin-lymphocyte Index as a Novel Biomarker for Progression in Patients Undergoing Surgery for Renal Cancer.C反应蛋白-白蛋白-淋巴细胞指数作为肾癌手术患者病情进展的新型生物标志物
Cancer Diagn Progn. 2024 Nov 3;4(6):748-753. doi: 10.21873/cdp.10391. eCollection 2024 Nov-Dec.
2
Pre-Treatment CRP-Albumin-Lymphocyte Index (CALLY Index) as a Prognostic Biomarker of Survival in Patients with Epithelial Ovarian Cancer.治疗前C反应蛋白-白蛋白-淋巴细胞指数(CALLY指数)作为上皮性卵巢癌患者生存的预后生物标志物
Cancer Manag Res. 2022 Sep 19;14:2803-2812. doi: 10.2147/CMAR.S359968. eCollection 2022.
3
Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).肾细胞癌肾切除术后 5 年以上复发相关特征:基于大型多中心数据库(CORONA/SATURN 项目)开发和内部验证预测晚期复发的风险模型(PRELANE 评分)。
Eur Urol. 2013 Sep;64(3):472-7. doi: 10.1016/j.eururo.2012.06.030. Epub 2012 Jun 22.
4
Clinical usefulness of C-reactive protein-albumin-lymphocyte (CALLY) index as a prognostic biomarker in patients undergoing surgical resection of pancreatic cancer.C 反应蛋白-白蛋白-淋巴细胞(CALLY)指数作为胰腺癌手术切除患者预后生物标志物的临床应用价值。
Langenbecks Arch Surg. 2024 Oct 21;409(1):317. doi: 10.1007/s00423-024-03512-8.
5
Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.嫌色细胞肾细胞癌(RCC):大型多中心系列中的肿瘤学结果和预后因素。
BJU Int. 2012 Jul;110(1):76-83. doi: 10.1111/j.1464-410X.2011.10690.x. Epub 2011 Nov 1.
6
Prognostic usefulness of the C-reactive protein-albumin-lymphocyte (CALLY) index as a novel biomarker in patients undergoing colorectal cancer surgery.C 反应蛋白-白蛋白-淋巴细胞(CALLY)指数作为结直肠癌手术患者新型生物标志物的预后价值。
Asian J Surg. 2024 Aug;47(8):3492-3498. doi: 10.1016/j.asjsur.2024.03.054. Epub 2024 Mar 26.
7
Multicenter Study of Controlling Nutritional Status (CONUT) Score as a Prognostic Factor in Patients With HIV-Related Renal Cell Carcinoma.多中心研究控制营养状况(CONUT)评分作为 HIV 相关肾细胞癌患者的预后因素。
Front Immunol. 2021 Nov 30;12:778746. doi: 10.3389/fimmu.2021.778746. eCollection 2021.
8
Prognostic Value of CRP-Albumin-Lymphocyte (CALLY) Index in Patients Undergoing Surgery for Breast Cancer.CRP-白蛋白-淋巴细胞(CALLY)指数在乳腺癌手术患者中的预后价值
Int J Gen Med. 2024 Mar 15;17:997-1005. doi: 10.2147/IJGM.S447201. eCollection 2024.
9
Clinical implications of C-reactive protein-albumin-lymphocyte (CALLY) index in patients with esophageal cancer.C 反应蛋白-白蛋白-淋巴细胞(CALLY)指数对食管癌患者的临床意义。
Surg Oncol. 2024 Apr;53:102044. doi: 10.1016/j.suronc.2024.102044. Epub 2024 Feb 5.
10
Prognostic significance of the preoperative C-reactive protein-albumin-lymphocyte (CALLY) index on outcomes after gastrectomy for gastric cancer.术前 C 反应蛋白-白蛋白-淋巴细胞(CALLY)指数对胃癌胃切除术后结局的预后意义。
Surg Today. 2024 Aug;54(8):943-952. doi: 10.1007/s00595-024-02813-1. Epub 2024 Mar 15.

引用本文的文献

1
Prognostic utility of the C-reactive protein-albumin-lymphocyte (CALLY) index in metastatic renal cell carcinoma.C反应蛋白-白蛋白-淋巴细胞(CALLY)指数在转移性肾细胞癌中的预后价值
BMC Cancer. 2025 Aug 20;25(1):1347. doi: 10.1186/s12885-025-14767-9.
2
Risk stratification for recurrence after nephrectomy in high-risk renal cell carcinoma patients.高危肾细胞癌患者肾切除术后复发的风险分层
Int J Clin Oncol. 2025 Jul 14. doi: 10.1007/s10147-025-02825-y.
3
Kidney Injury Molecule-1 as a Biomarker for Renal Cancer: Current Insights and Future Perspectives-A Narrative Review.

本文引用的文献

1
CRP-albumin-lymphocyte (CALLY) Index Is an Independent Prognostic Factor for the Esophageal Cancer Patients Who Received Curative Treatment.CRP-白蛋白-淋巴细胞(CALLY)指数是接受根治性治疗的食管癌患者的独立预后因素。
Anticancer Res. 2024 Feb;44(2):815-822. doi: 10.21873/anticanres.16873.
2
Clinical significance of preoperative CALLY index for prognostication in patients with esophageal squamous cell carcinoma undergoing surgery.术前 CALLY 指数对接受手术治疗的食管鳞癌患者预后预测的临床意义。
Sci Rep. 2024 Jan 6;14(1):713. doi: 10.1038/s41598-023-51109-w.
3
Superiority of CRP-albumin-lymphocyte index as a prognostic biomarker for patients with gastric cancer.
肾损伤分子-1作为肾癌生物标志物:当前见解与未来展望——一篇叙述性综述
Int J Mol Sci. 2025 Apr 6;26(7):3431. doi: 10.3390/ijms26073431.
C反应蛋白-白蛋白-淋巴细胞指数作为胃癌患者预后生物标志物的优越性
Nutrition. 2023 Dec;116:112191. doi: 10.1016/j.nut.2023.112191. Epub 2023 Aug 10.
4
Prognostic significance of the preoperative platelet-lymphocyte ratio in nonmetastatic renal cell carcinoma: cross-sectional study.术前血小板-淋巴细胞比值在非转移性肾细胞癌中的预后意义:横断面研究
Ann Med Surg (Lond). 2023 Jun 7;85(8):3833-3837. doi: 10.1097/MS9.0000000000000862. eCollection 2023 Aug.
5
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.帕博利珠单抗对比安慰剂用于肾透明细胞癌肾切除术患者的辅助治疗(KEYNOTE-564):一项多中心、随机、双盲、安慰剂对照、III 期临床试验的 30 个月随访分析。
Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9.
6
Neutrophil-to-Lymphocyte Ratio Predicts Cancer Outcome in Locally Advanced Clear Renal Cell Carcinoma.中性粒细胞与淋巴细胞比值预测局部进展期透明细胞肾细胞癌的肿瘤结局。
Clin Genitourin Cancer. 2022 Apr;20(2):102-106. doi: 10.1016/j.clgc.2021.10.009. Epub 2021 Nov 22.
7
The Role of C-Reactive Protein in Kidney, Bladder, and Prostate Cancers.C反应蛋白在肾癌、膀胱癌和前列腺癌中的作用。
Front Immunol. 2021 Aug 27;12:721989. doi: 10.3389/fimmu.2021.721989. eCollection 2021.
8
Superiority of CRP-albumin-lymphocyte index (CALLY index) as a non-invasive prognostic biomarker after hepatectomy for hepatocellular carcinoma.CRP-白蛋白-淋巴细胞指数(CALLY 指数)作为肝癌肝切除术后非侵入性预后生物标志物的优越性。
HPB (Oxford). 2022 Jan;24(1):101-115. doi: 10.1016/j.hpb.2021.06.414. Epub 2021 Jun 22.
9
Sarcomatoid renal cell carcinoma: biology, natural history and management.肉瘤样肾细胞癌:生物学、自然史与治疗。
Nat Rev Urol. 2020 Dec;17(12):659-678. doi: 10.1038/s41585-020-00382-9. Epub 2020 Oct 13.
10
Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data.局限性肾细胞癌的复发:当代数据的系统评价
Curr Urol Rep. 2017 Feb;18(2):15. doi: 10.1007/s11934-017-0661-3.